Vestibular Prodrome and Hearing Loss Treatment Case Study

Acute Low-Tone Hearing Loss (ALHL) is not just a hearing problem. It is a specific audiometric pattern—a sensorineural loss primarily in the lower frequencies—that signals a potentially progressive inner ear disorder. According to research by Marsella Lulu Aulia and Gustav Syukrinto, ALHL is often the clinical manifestation of cochlear-restricted endolymphatic hydrops (EH). This means it represents an abnormal buildup of fluid in the inner ear, making it a strong precursor to Menière’s Disease (MD). The clinical implication is stark: this condition is highly prone to recurrence and progression, necessitating urgent and aggressive treatment.

The Direct Link Between ALHL and Endolymphatic Hydrops

The core finding of the research is that ALHL is best understood as a form of cochlear EH. Endolymphatic hydrops is the pathological hallmark of Menière’s Disease, characterized by excess fluid pressure in the membranous labyrinth. When this process is initially restricted to the cochlea, it manifests as ALHL—unilateral hearing loss for low-pitched sounds, accompanied by tinnitus, aural fullness, and often subtle dizziness or imbalance. The case report of a 27-year-old female with these exact symptoms, confirmed by pure-tone audiometry, exemplifies this presentation. Recognizing ALHL as hydrops changes the treatment goal from simply recovering hearing to stabilizing the entire inner ear environment to prevent irreversible progression.

Immediate Treatment: High-Dose Corticosteroids

Given the risk of progression, the research emphasizes immediate intervention. The primary recommendation is high-dose corticosteroid therapy. Steroids work by reducing inflammation and swelling in the inner ear, potentially stabilizing the delicate fluid balance. This approach is consistent with protocols for sudden sensorineural hearing loss (SSNHL), though ALHL presents a distinct sub-type. The urgency stems from the need to address the inflammatory component of hydrops early, aiming for complete recovery and preventing the condition from establishing a chronic pattern. For a detailed review of corticosteroid use in hearing loss, see our related article on Corticosteroid Treatment for Sudden Hearing Loss.

Supporting Inner Ear Fluid Balance with Anti-Hydrops Agents

Beyond steroids, management often includes “anti-hydrops” agents. These are medications aimed directly at the presumed fluid imbalance. Common options include diuretics, which reduce systemic fluid retention, or betahistine, a drug thought to improve microcirculation in the inner ear. This dual approach—steroids for acute inflammation and anti-hydrops agents for the underlying pathophysiology—forms the aggressive therapeutic strategy needed. It is important to distinguish this sensorineural loss from conductive issues; a clear diagnosis is essential, as outlined in our guide to Conductive Hearing Loss: Diagnosis & Management Guide.

The Necessity of Long-Term Audio Vestibular Surveillance

A single episode of ALHL is not a closed case. The research underscores that comprehensive and prolonged surveillance is a critical part of management. Patients require regular pure-tone audiometric evaluations to monitor for recurrence or progression of hearing loss. Vestibular function should also be assessed, as the hydrops may spread from the cochlea to the balance organs, leading to more definitive Menière’s Disease with rotational vertigo. This long-term monitoring strategy acknowledges that ALHL is often a fluctuating, unstable condition rather than a one-time event.

Practical Implications for Patients and Clinicians

For patients presenting with sudden low-frequency hearing loss, fullness, and dizziness, this research signals a clear action path. First, obtain a prompt and accurate audiometric diagnosis. Second, initiate high-dose steroid treatment without delay, often combined with anti-hydrops medication. Third, commit to a long-term plan of regular check-ups with an audiologist or otologist, even after symptoms resolve. For clinicians, the takeaway is to treat ALHL with the seriousness reserved for Menière’s Disease precursors, not as a benign or isolated hearing loss. The neurological aspects of related conditions, such as the brain changes in hyperacusis, further illustrate the complex interplay between ear pathology and central processing, as discussed in Hyperacusis Brain Changes: MRI Review.

The study by Aulia and Syukrinto, available via DOI: 10.59141/-.v8i1.503, consolidates a management approach that is both aggressive and vigilant. By viewing ALHL as cochlear hydrops, treatment focuses on the root cause, aiming not only for hearing recovery but for preventing a lifetime of vestibular disorder.